Eli Lilly and Company (LLY) Form 4 Filings

ELI LILLY & Co director Gabrielle Sulzberger reported an equity award under the company’s director compensation program. On the reported date, she acquired 4.786 shares of common stock at a reference price of $1,036.05 per share through a grant or award transaction.

According to the footnote, she elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in common shares after she separates from service. Following this award, her directly held common stock balance reported in this filing is 2,966.222 shares.

ELI LILLY & Co director Juan R. Luciano reported an acquisition of 15.363 shares of common stock at $1,036.05 per share through a grant or award. At his election, this compensation was deferred into stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following this award, he directly owns 16,772.019 shares of common stock.

ELI LILLY & Co director J. Erik Fyrwald reported an equity award tied to his board compensation. On the reported date, he acquired 9.572 shares of common stock at a reference price of $1,036.05 per share, bringing his directly held total to 75,120.322 shares. According to the disclosure, he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in shares of common stock after he separates from board service.

ELI LILLY & Co director Ralph Alvarez reported an equity award tied to his board compensation. He acquired 11.985 shares of common stock on February 17, 2026 at a reference price of $1,036.05 per share as a grant, bringing his directly held stake to 55,491.627 shares.

According to the disclosure, he elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, which will be settled in common shares after he leaves board service. The filing also reports 758 shares held indirectly by a trust, with Alvarez disclaiming beneficial ownership beyond his economic interest.

ELI LILLY & Co SVP Donald A. Zakrowski exercised restricted stock units and had shares withheld for taxes. On the transaction date, 184 restricted stock units were converted into 184 common shares at $0.00 per share. To satisfy tax obligations, 81.553 common shares were disposed of at $1040.00 per share, leaving 3,525.89 directly owned shares and 1,728.57 common shares held indirectly through a 401(k) plan. Each restricted stock unit represents a contingent right to receive one share of common stock.

Eli Lilly & Co EVP & CFO Montarce Lucas reported equity award activity involving company stock. Lucas exercised or converted 368 restricted stock units, receiving the same number of Eli Lilly common shares. To cover tax obligations, 159.733 common shares were disposed of in a tax-withholding transaction at $1040 per share, leaving 16,258.473 common shares owned directly after these transactions.

Eli Lilly & Co executive Kenneth L. Custer reported routine equity transactions. On February 16, he exercised 207 restricted stock units, receiving 207 shares of common stock at no cost. On the same date, 91.311 shares were disposed of at $1,040 per share to satisfy tax withholding obligations, leaving him with 10,140.544 directly owned shares.

Adrienne S. Brown, EVP and President of Lilly Immunology at Eli Lilly & Co, exercised restricted stock units into common shares and had shares withheld to cover taxes. On the transaction date, 391 restricted stock units were converted into 391 shares of common stock at a stated price of $0.0000 per share.

Following this derivative exercise/conversion, a tax-withholding disposition of 169.966 common shares was reported at $1040.0000 per share to satisfy tax obligations. After these transactions, Brown directly owned 5,142.342 shares of Eli Lilly common stock.

Eli Lilly executive insider filing shows a corrected share adjustment. On February 9, 2026, the reporting officer (EVP & CIDO) is shown as having acquired 4,599.164 shares of Eli Lilly common stock at $1,044.67 per share. After this adjustment, the executive directly owns 26,396.534 shares. The accompanying note explains this amended Form 4 corrects an earlier over-withholding of shares for tax obligations caused by an administrative error.

Eli Lilly & Co senior vice president, finance, and chief accounting officer Donald A. Zakrowski acquired additional company equity on February 9, 2026. He received 583.784 shares of common stock as a grant or award at $1,044.67 per share, bringing his directly held common stock to 3,423.443 shares.

He also received a grant of 199.472 restricted stock units, each representing a contingent right to one share of common stock, with both exercisable and expiration dates of February 16, 2029. In addition, 1,728.57 common shares are held indirectly through a 401(k) plan.

Eli Lilly executive Ilya Yuffa reported an acquisition of company stock through an equity award. On 02/09/2026, he received 4,162.504 shares of Eli Lilly common stock in a grant or other acquisition at a price of $1,044.67 per share. Following this award, he directly holds 32,304.111 shares of Eli Lilly common stock as EVP & President, LLY USA & Global Capabilities.

Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, acquired 4,865.888 shares of Eli Lilly common stock on February 9, 2026 through a grant or award at $1,044.67 per share. Following this award, he directly holds 26,626.498 common shares. He also has indirect holdings of 4,342 shares through the Van Naarden Family Trust and 5,302 shares through a spousal lifetime access trust. The transactions are reported with a disclaimer that he only beneficially owns the securities to the extent of his pecuniary interest, and a footnote explains a February 5, 2026 transfer of 5,302 spouse-held shares into the spousal lifetime access trust, including 1,000 shares previously misreported as directly held.

Eli Lilly & Co. executive Daniel Skovronsky reported an acquisition of company common stock through a grant or award. On 02/09/2026, he received 15,547.862 shares at a price of $1,044.67 per share, bringing his directly held stake to 160,071.725 shares, with additional indirect holdings through a trust and spouse-related entities.

Ricks David A reported acquisition or exercise transactions in this Form 4 filing.

Eli Lilly & Co President, Chair, CEO and director David A. Ricks received a grant of 38,913.584 shares of common stock on February 9, 2026 at $1,044.67 per share. Following this award, he directly held 571,715.097 common shares.

He also reported indirect holdings through several vehicles, including the David A. Ricks 2025 GRAT, the David A. Ricks 2022 GRAT, a trust, the David A. Ricks SLAT, and a 401(k) account, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Eli Lilly executive Diogo Rau reported an equity award in company stock. On 02/09/2026, the EVP & CIDO acquired 4,432.32 shares of Eli Lilly common stock through a grant or award at a price of $1,044.67 per share. Following this transaction, Rau directly beneficially owned 26,229.69 shares of Eli Lilly common stock.

Montarce Lucas reported acquisition or exercise transactions in this Form 4 filing.

Eli Lilly & Co. executive vice president and chief financial officer Lucas Montarce reported receiving a stock award of 1,365.47 shares of common stock on February 9, 2026. The award was recorded at a price of $1,044.67 per share, bringing his directly held stake to 16,050.206 shares.

Eli Lilly executive Patrik Jonsson, EVP & President, LLY International, reported an acquisition of company stock through an equity award. On 02/09/2026 he received 4,818.052 shares of common stock at $1,044.67 per share, bringing his directly held stake to 60,646.62 shares, with additional indirect holdings in a 401(k) plan.

Eli Lilly executive Edgardo Hernandez reported an equity award of company stock. On 02/09/2026, he acquired 4,383.734 shares of Eli Lilly common stock in a grant or award at $1,044.67 per share. Following this award, he directly holds 46,095.717 shares and indirectly holds 871.35 shares through a 401(k) plan.

Eli Lilly and Company executive Anat Hakim, EVP, GC & Secretary, reported an acquisition of common stock through a grant or award. On 02/09/2026, she acquired 8,277.919 shares of Eli Lilly common stock at $1,044.67 per share, bringing her directly held stake to 22,987.024 shares.

The filing also notes indirect holdings of 15,700 shares held by the Anat Hakim SLAT and 16,875 shares held by her spouse, with a disclaimer that she disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Eli Lilly & Co

Eli Lilly executive Kenneth L. Custer reported an equity award of company stock. On 02/09/2026, he acquired 659.28 shares of Eli Lilly common stock as a grant or award at a value of $1,044.67 per share. Following this non‑open‑market acquisition, he directly holds 10,024.855 Eli Lilly shares.

Eli Lilly and Company executive Adrienne S. Brown reported an acquisition of company stock. On February 9, 2026, the EVP, President LLY Imm received a grant or award of 1,196.308 shares of Eli Lilly common stock at $1,044.67 per share. Following this award, Brown directly beneficially owned 4,921.308 shares of Eli Lilly common stock.

Eli Lilly executive Ilya Yuffa reported equity compensation activity involving company stock. On February 1, 2026, 3,394 restricted stock units converted into an equal number of Eli Lilly common shares at an exercise price of $0, reflecting a standard vesting event.

On the same date, 1,512.364 shares of common stock were disposed of at $1,037.15 per share in a transaction coded “F,” indicating shares withheld to cover taxes related to the vesting. After these transactions, Yuffa directly owned 28,141.607 Eli Lilly common shares.

Eli Lilly EVP Daniel Skovronsky reported equity transactions on February 1, 2026. He exercised 12,684 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.

To cover related obligations, 5,641.249 common shares were withheld at a price of $1,037.15 per share. After these transactions, he directly holds 144,523.863 Eli Lilly common shares, with additional indirect holdings of 72,359 shares by a trust, 547 shares by his spouse, and 2,710 shares by his spouse's SLAT. He disclaims beneficial ownership of these reported securities except to the extent of his pecuniary interest.

Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, reported equity movements in Eli Lilly common stock. On February 1, 2026, 4,108 restricted stock units were converted into the same number of common shares at an exercise price of $0, bringing his directly held common stock to 24,669.985 shares.

On the same date, 1,909.375 shares of common stock were withheld at a price of $1,037.15 per share, typically for tax obligations, leaving him with 22,760.61 shares of Eli Lilly common stock held directly. Separately, 4,342 shares are held indirectly through the Van Naarden Family Trust and 4,302 shares are held indirectly by his spouse. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Eli Lilly President, Chair, and CEO David A. Ricks reported equity award activity involving company stock on February 1, 2026. He exercised 31,932 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.

On the same date, he disposed of 14,296.654 common shares at $1,037.15 per share, leaving 532,801.513 common shares held directly after the reported transactions. Additional indirect holdings are reported through several trusts, GRATs, a SLAT, and a 401(k) plan, with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Eli Lilly executive Diogo Rau reported routine equity compensation activity. On February 1, 2026, 3,752 restricted stock units converted into the same number of Eli Lilly common shares at an exercise price of $0, increasing his directly held stock.

On the same day, 1,673.538 shares of common stock were withheld at a price of $1,037.15 per share, a transaction coded “F,” which typically reflects shares retained to cover taxes on vested awards. After these transactions, Rau directly owned 21,797.37 Eli Lilly common shares.

Eli Lilly executive Patrik Jonsson, EVP & President, LLY International, reported equity transactions in company stock on February 1, 2026. He exercised 3,930 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.

To cover taxes from this vesting, 1,752.071 shares of common stock were withheld or disposed of at $1,037.15 per share under transaction code "F." After these transactions, Jonsson directly owned 55,828.568 shares of Eli Lilly common stock and indirectly held 608.95 shares through a 401(k) plan.

Eli Lilly and Company executive Edgardo Hernandez reported equity transactions involving company stock. On February 1, 2026, 3,572 restricted stock units converted into the same number of Eli Lilly common shares at $0 exercise price. On the same date, 1,591.452 common shares were disposed of at $1,037.15 per share.

After these transactions, Hernandez directly held 41,711.983 Eli Lilly common shares and indirectly held 871.94 shares through a 401(k) plan. Each restricted stock unit represents a contingent right to receive one Eli Lilly common share.

Eli Lilly & Co executive Anat Hakim reported routine equity transactions involving restricted stock units and common shares. On 02/01/2026, she converted 6,700 restricted stock units into Eli Lilly common stock at an exercise price of $0.

On the same date, 2,953.395 shares of common stock were withheld at a price of $1,037.15 in a transaction coded "F," typically used for tax withholding, leaving 14,709.105 common shares held directly. Additional indirect holdings are 15,700 common shares held by the Anat Hakim SLAT and 16,875 common shares held by her spouse. She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Eli Lilly executive Eric Dozier, EVP and Chief People Officer, reported several equity transactions dated February 1, 2026. A block of 2,858 restricted stock units converted into the same number of Eli Lilly common shares at $0 per share, increasing his direct holdings. On the same date, a disposition coded “F” covered 1,272.992 common shares at $1,037.15 per share, leaving Dozier with 11,423.918 common shares held directly. He also reports an additional 376.93 common shares held indirectly through a 401(k) account.

Eli Lilly and Company director Gabrielle Sulzberger reported a small acquisition of company stock as part of board compensation. On January 20, 2026, she acquired 4.762 shares of Eli Lilly common stock at a price of $1,041.29 per share, bringing her directly held beneficial ownership to 2,961.436 shares.

According to the filing, these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They are credited as stock units and are scheduled to be settled in actual shares of common stock after her separation from service as a director. The transaction reflects routine director compensation rather than an open-market purchase or sale.

Eli Lilly and Company director Juan R. Luciano reported an acquisition of company common stock through the deferral of board compensation. On January 20, 2026, he acquired 15.286 shares of Eli Lilly common stock at a price of $1,041.29 per share, recorded as an "A" transaction. After this transaction, he beneficially owned 16,756.656 shares of Eli Lilly common stock in direct ownership.

According to the disclosure, Mr. Luciano elected to defer his cash compensation into stock units under the Lilly Directors' Deferral Plan. These deferred stock units will be settled in shares of common stock after he separates from service as a director, meaning the award is part of his director compensation structure rather than an open-market purchase.

Eli Lilly & Co. director J. Erik Fyrwald reported an acquisition of company common stock through a compensation deferral arrangement. On January 20, 2026, he acquired 9.523 shares of Eli Lilly common stock at $1,041.29 per share, increasing his directly held beneficial ownership to 75,110.75 shares.

According to the disclosure, these shares were not received as immediate cash pay but were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They will be settled in shares of common stock after Fyrwald separates from service as a director, reflecting standard equity-based director compensation rather than an open-market trade.

Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.924 shares of Eli Lilly common stock on January 20, 2026. According to the filing, this amount represents fees that he elected to defer as stock units under the Lilly Directors' Deferral Plan, instead of taking cash, and these units will be settled in Eli Lilly common shares after he leaves board service.

Following this transaction, Alvarez directly beneficially owned 55,479.642 shares of Eli Lilly common stock. The filing also reports an additional 758 shares held indirectly through a trust, for which he disclaims beneficial ownership except to the extent of his economic interest.

Lilly Endowment Inc., a more than 10% owner of Eli Lilly and Company (LLY), reported a series of open-market sales of Eli Lilly common stock on January 7, 2026. The Form 4 shows multiple block sales at weighted average prices generally between $1,085.108 and $1,116.686 per share, with each price reflecting numerous individual trades within narrow ranges as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owned 91,896,978 shares of Eli Lilly common stock held directly.

Lilly Endowment Inc., a more than 10% owner of Eli Lilly & Co. (LLY), reported a sale of company stock. On 01/05/2026, the reporting person sold 1,390 shares of Eli Lilly common stock at a weighted average price of $1,085.011 per share. The sale was executed in multiple trades at prices ranging from $1,085.00 to $1,085.10.

Following this transaction, the reporting person beneficially owned 92,189,126 shares of Eli Lilly common stock in direct ownership. The filing notes that detailed trade-by-trade pricing information within the reported range will be provided upon request. The form was signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.

Eli Lilly & Co reported an insider transaction by a director-level reporting person. On 12/29/2025, the reporting person sold 3,593 shares of Eli Lilly common stock in an open-market transaction coded "S".

The weighted average sale price was $1,085.035 per share, with individual trades executed between $1,085.00 and $1,085.245. After this sale, the reporting person directly beneficially owned 92,190,516 Eli Lilly shares.

ELI LILLY & Co reported an insider transaction involving its stock. On 12/24/2025, the reporting person sold 2,629 shares of Eli Lilly common stock, listed with transaction code "S". The weighted average sale price was $1,085.173 per share, with individual trades executed between $1,085.00 and $1,085.53.

After this sale, the reporting person beneficially owned 92,194,109 shares of Eli Lilly common stock, held in direct ownership. The footnote explains that detailed trade information within the price range is available upon request from Eli Lilly & Company, its security holders, or the SEC staff.

Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co., reported a small open-market sale of company stock. On 12/23/2025, the reporting person sold 240 shares of common stock, coded as a sale transaction, at a weighted average price of $1,085.038 per share.

The shares were sold in multiple trades at prices ranging from $1,085.00 to $1,085.08. After this transaction, the reporting person beneficially owned 92,196,738 shares of Eli Lilly common stock in direct ownership form. The filer has undertaken to provide detailed trade breakdowns upon request to the company, its security holders, or the SEC staff.

Eli Lilly director Gabrielle Sulzberger reported acquiring 4.668 shares of the company’s common stock on 12/15/2025 at $1,062.19 per share in an insider transaction. Following this transaction, she beneficially owns 2,956.674 shares directly.

The shares were acquired by deferring cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after her separation from service.

Eli Lilly & Co director Juan R. Luciano reported acquiring 13.965 shares of common stock on 12/15/2025 in a transaction coded “A” for acquisition at a price of $1,062.19 per share. After this transaction, he beneficially owned 16,741.37 shares held directly.

The shares acquired have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following Luciano’s separation from service with the company.

Eli Lilly & Co director Mary Lynne Hedley reported acquiring 9.336 shares of Eli Lilly common stock on 12/15/2025 at a price of $1,062.19 per share. According to the filing, at her election these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following her separation from service.

After this transaction, she beneficially owned 2,252.694 shares of Eli Lilly common stock directly and 98 shares indirectly through a trust, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.

Eli Lilly and Company director J. Erik Fyrwald elected to receive 9.336 stock units tied to Eli Lilly common stock on 12/15/2025 instead of cash compensation. The units were valued at $1,062.19 each under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after his separation from service.

After this transaction, Fyrwald beneficially owns 75,101.227 shares of Eli Lilly common stock in direct holdings.

Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.062 shares of Eli Lilly common stock on 12/15/2025 at a price of $1,062.19 per share. According to the filing, these shares were credited as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in shares of common stock after he separates from service as a director.

After this transaction, Alvarez beneficially owned 55,467.718 shares of Eli Lilly common stock directly and 758 shares indirectly through a trust, with the indirect ownership reported only to the extent of his pecuniary interest.

Eli Lilly & Co. (LLY) director Lilly Endowment Inc. reported open-market sales of Eli Lilly common stock on 11/25/2025. The Endowment sold 5,043 shares at a weighted average price of $1,108.71, 9,249 shares at a weighted average price of $1,109.449, and 1,340 shares at a weighted average price of $1,110.527, for a total of 15,632 shares sold.

After these transactions, Lilly Endowment Inc. beneficially owned 92,196,978 shares of Eli Lilly common stock, held directly. The prices reported reflect multiple trades within narrow ranges for each block of shares. This filing is identified as the second of two Forms 4 filed by the reporting person on the same date, covering transactions numbered 31 through 33 of 33 total transactions.

Lilly Endowment Inc., a director-level reporting person of Eli Lilly & Co (LLY), reported a series of open-market sales of Eli Lilly common stock on 11/25/2025. The Form 4 lists 30 separate sale transactions, each coded as an "S" for sale, with weighted average prices including $1,073.735 and $1,107.48 per share, and footnotes detailing underlying trade ranges from $1,073.78 to $1,107.95. After completing these reported sales, Lilly Endowment Inc. beneficially owned 92,212,610 shares of Eli Lilly common stock, held directly. This filing is identified as the first of two Forms 4 filed the same day, covering transactions numbered 1 through 30 of 33 total.

Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co (LLY), reported multiple sales of Eli Lilly common stock on 11/24/2025. The largest block shown was 120,016 shares sold at a weighted average price of $1,068.175 per share, with additional smaller sales the same day at weighted average prices between about $1,069.477 and $1,073.597 per share.

After these transactions, Lilly Endowment directly beneficially owned 92,359,671 shares of Eli Lilly common stock. The prices reported are weighted averages for multiple trades within narrow price ranges, and the reporting person has indicated a willingness to provide detailed trade breakdowns upon request.

Eli Lilly & Co. (LLY) reported a series of share sales by a 10% owner on 11/21/2025. The Form 4 shows Lilly Endowment Inc., filing as a single reporting person, disposing of multiple blocks of common stock in open-market transactions coded "S" for sale.

The reported trades cover numerous small tranches, such as 9,871 shares at a weighted average price of $1,050.272 and 23,916 shares at $1,059.658, with additional sales at prices generally between about $1,050 and $1,066.15. After these transactions, the reporting person beneficially owned 92,501,978 shares of Eli Lilly common stock, held directly.